Needham downgrades Biogen on slow growth of Alzheimer's drug
Needham downgraded Biogen Inc (NASDAQ:BIIB) on Monday, citing slower-than-expected growth for its Alzheimer's drug, Leqembi, and a lack of major catalysts over the next 12 months.
Medscape4d
Leqembi Okayed for Subset of Early Alzheimer’s Patients
The European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization for Leqembi ... in their CDR-SB score, while those ...
FiercePharma4d
EMA changes tune, endorses Eisai and Biogen's Leqembi in restricted Alzheimer's population
The increase on CDR-SB score was 1.22 for Leqembi and 1.75 for a dummy drug, where higher numbers indicate greater impairment. Leqembi's vial design could result in hundreds of millions in annual ...
The Boston Globe19d
Biogen raises forecast as Alzheimer’s drug Leqembi shows signs of growth
The stock is down 29 percent this year as of Tuesday’s close, largely due to a sluggish start for Leqembi — on the market to treat Alzheimer’s since January 2023 — and the recent rejection ...